American Journal of Cardiology最新文献

{"title":"Colchicine in Patients With Coronary Disease Who Underwent Coronary Artery Bypass Surgery: A Meta-Analysis of Randomized Controlled Trials","authors":"Hristo Kirov MD ,&nbsp;Tulio Caldonazo MD ,&nbsp;Angelique Runkel MS ,&nbsp;Darko Medin MS ,&nbsp;Johannes Fischer MS ,&nbsp;Luis Roberto Dallan MD ,&nbsp;Murat Mukharyamov MD ,&nbsp;Omar A. Mejia MD, PhD ,&nbsp;Fabio B. Jatene MD, PhD ,&nbsp;Torsten Doenst MD, PhD","doi":"10.1016/j.amjcard.2024.09.003","DOIUrl":"10.1016/j.amjcard.2024.09.003","url":null,"abstract":"<div><div>Recent randomized evidence has shown that low-dose colchicine lowers the risk of cardiovascular events in patients with chronic coronary artery disease. Colchicine has also been used in coronary artery bypass grafting (CABG), with individual studies suggesting protective effects for postoperative atrial fibrillation (POAF). We performed a meta-analysis of studies assessing the effect of colchicine on outcomes in CABG surgery. We systematically searched 3 libraries (MEDLINE, Web of Science, and the Cochrane Library), selecting all randomized control trials including patients who underwent CABG and were randomized for perioperative administration of colchicine versus standard of care. The primary outcome was incidence of POAF. The inverse variance method (DerSimonian&amp;Laird) and random-effects model were performed. The leave-one-out analysis was carried out as a sensitivity analysis to address possible outliers. From 205 screened studies, 5 met the inclusion criteria and were selected. The data from 839 patients were included in the final analysis. The included studies were published between 2014 and 2022. The perioperative administration of colchicine was associated with the reduction of POAF rates after CABG compared with standard of care (relative risk 0.54, 95% confidence interval 0.40 to 0.73, p &lt;0.01). The leave-one-out analysis confirmed the robustness of the analysis, with minimal variations of the confidence interval. This meta-analysis of randomized studies suggests that the perioperative administration of colchicine is associated with significant reduction of POAF after CABG.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0002914924006532/pdfft?md5=d95abb4820b81cada0007d4c13df07ec&pid=1-s2.0-S0002914924006532-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Stenting Long Lesions on Clinical Outcomes in Patients Presenting With Acute Coronary Syndrome and Multivessel Disease: Data From the BIOVASC Trial","authors":"Hala Kakar MD ,&nbsp;Jacob J. Elscot BSc ,&nbsp;Annebel de Gier BSc ,&nbsp;Wijnand K. Den Dekker MD, PhD ,&nbsp;Johan Bennett MD, PhD ,&nbsp;Manel Sabaté MD, PhD ,&nbsp;Giovanni Esposito MD, PhD ,&nbsp;Eric Boersma MD, PhD ,&nbsp;Nicolas M. Van Mieghem MD, PhD ,&nbsp;Roberto Diletti MD, PhD ,&nbsp;BIOVASC investigators","doi":"10.1016/j.amjcard.2024.08.024","DOIUrl":"10.1016/j.amjcard.2024.08.024","url":null,"abstract":"<div><div>An increased total stent length (TSL) might be associated with a higher risk of clinical events; however, in patients with multivessel disease (MVD), a considerable TSL is often required. In patients presenting with acute coronary syndrome and MVD, immediate complete revascularization was associated with shorter TSL in the BIOVASC (Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease) Trial. This is a subanalysis of the BIOVASC trial comparing clinical outcomes in patients with either &lt;60 or ≥60 mm TSL. The primary outcome was a composite of all-cause mortality, myocardial infarction, any unplanned ischemia driven revascularization, or cerebrovascular events at 2 years after the index procedure. A total of 1,525 patients were enrolled in the BIOVASC trial, of whom 855 had a TSL of ≥60 mm (long TSL). No significant difference was established when comparing patients treated with either long or short TSL in terms of the primary outcome at 2-year follow-up, which occurred in 117 patients (13.7%) in the ≥60 mm group and 69 patients (10.3%) in the &lt;60 mm group (adjusted hazard ratio 1.25, 95% confidence interval 0.92 to 1.69, p = 0.16). Furthermore, no significant differences were observed in the secondary end points. In conclusion, in patients with acute coronary syndrome and MVD, long stenting did not show a significant difference in clinical event rate compared with short stenting.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arteriosclerotic Calcification and Atrial Fibrillation in the General Population: The Rotterdam Study","authors":"Sven Geurts MD, MSc ,&nbsp;Maxime M. Bos PhD ,&nbsp;Janine E. van der Toorn MSc ,&nbsp;Bruno H.C. Stricker MD, PhD ,&nbsp;Mohsen Ghanbari MD, PhD ,&nbsp;Jan A. Kors PhD ,&nbsp;Jaap W. Deckers MD, PhD ,&nbsp;M. Arfan Ikram MD, PhD ,&nbsp;Daniel Bos MD, PhD ,&nbsp;Maryam Kavousi MD, PhD","doi":"10.1016/j.amjcard.2024.09.002","DOIUrl":"10.1016/j.amjcard.2024.09.002","url":null,"abstract":"<div><div>Limited population-based data on the gender differences and association between arteriosclerotic calcification at different sites and atrial fibrillation (AF) exist. We aimed to investigate the (gender-specific) associations between arteriosclerotic calcification at different sites with the risk of AF in the general population. Arteriosclerotic calcification was quantified using computed tomography examinations between 2003 and 2006 in 2,259 participants free of AF from the population-based Rotterdam Study. Cox proportional hazards models, adjusted for cardiovascular risk factors, were used to assess the associations of volumes of coronary artery calcification (CAC), aortic arch calcification (AAC), extracranial and intracranial carotid arteries, vertebrobasilar arteries, and the aortic valve with incident AF. During a median follow-up of 8.6 years, 182 incident AF cases occurred. A larger CAC was associated with incident AF (hazard ratio [HR], 95% confidence interval [CI] 1.25 1.09 to 1.44, p = 0.0019). The gender-stratified analyses showed that larger CAC in men (HR 1.43, 95% CI 1.10 to 1.86, p = 0.0068) and larger AAC in women were associated with incident AF (HR1.44, 95% CI 1.04 to 2.01, p = 0.0299). In conclusion, CAC in the general population, especially in men, and AAC in women were significantly associated with new-onset AF. Our findings imply that interventions to lower arteriosclerotic calcification, particularly, CAC, carry potential for the prevention of AF in the general population, especially in men.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Half-Time Score or Final?","authors":"David T. Linker MD","doi":"10.1016/j.amjcard.2024.08.031","DOIUrl":"10.1016/j.amjcard.2024.08.031","url":null,"abstract":"","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Belgian Registry on Coronary Function Testing (BELmicro Registry): Study Population, Prevalence of Coronary Vascular Dysfunction, and Procedural Safety","authors":"Tijs Bringmans MD ,&nbsp;Alice Benedetti MD ,&nbsp;Carlo Zivelonghi MD, PhD, MSc ,&nbsp;Maarten Vanhaverbeke MD, PhD ,&nbsp;Frédéric Daniel Mathieu MD ,&nbsp;Pieter-Jan Palmers MD ,&nbsp;Patrick Coussement MD ,&nbsp;Kenneth De Wilder MD ,&nbsp;Bert Everaert MD, PhD ,&nbsp;Mathieu Coeman MD ,&nbsp;Fabian Demeure MD, PhD ,&nbsp;Maarten Kersemans MD ,&nbsp;Carlos Collet Bortone MD, PhD ,&nbsp;Peter Kayaert MD, PhD ,&nbsp;Carlos Van Mieghem MD, PhD ,&nbsp;Vincent Frans Maria Segers MD, PhD","doi":"10.1016/j.amjcard.2024.08.035","DOIUrl":"10.1016/j.amjcard.2024.08.035","url":null,"abstract":"<div><div>Coronary function testing (CFT) plays a pivotal role in the diagnosis of coronary vascular dysfunction and providing patients with tailored therapy. The Belgian registry on CFT (BELmicro registry) is a prospective, observational, multicenter registry including 14 centers in Belgium. All patients who underwent clinically indicated CFT were included in the registry. Baseline characteristics, CFT data, and clinical outcomes were collected. This analysis aimed to describe the baseline characteristics of a real-world population of patients who underwent CFT, evaluate the prevalence of coronary vascular dysfunction, and assess the safety of CFT in daily clinical practice. Between October 2021 and September 2023, 449 patients were enrolled. The mean age was 65 ± 10 years, and 47.4% of patients were men. A total of 59% of patients had hypertension, 18.7% had diabetes, 69.5% had hypercholesterolemia, and 40.1% had a smoking habit. Angina and nonobstructive coronary arteries (ANOCAs) were identified in 85.1% of the patients. Microvascular physiology assessment was performed in 95.5% of patients, vasoreactivity test in 28.5%, and both in 24.0%. coronary microvascular dysfunction was diagnosed in 23.4% of patients with ANOCA, epicardial vasospasm in 26.3%, and microvascular spasm in 14.9%. Rates of major complications were 0.7% for microvascular physiology assessment and 0% for vasoreactivity test. In conclusion, participants in the BELmicro registry represented a real-world population of patients, characterized by a high burden of cardiovascular risk factors. Coronary microvascular dysfunction and coronary vasospasm were frequent in patients with ANOCA. Performing CFT in daily clinical practice was feasible, with a low rate of complications.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence, Time Course, and Outcomes of Worsening Tricuspid Regurgitation Following Transvenous Cardiac Implantable Electronic Device Implantation","authors":"Kitae Kim MD,&nbsp;Ryosuke Murai MD,&nbsp;Taiji Okada MD,&nbsp;Toshiaki Toyota MD,&nbsp;Yasuhiro Sasaki MD,&nbsp;Tomohiko Taniguchi MD,&nbsp;Natsuhiko Ehara MD,&nbsp;Atsushi Kobori MD,&nbsp;Makoto Kinoshita MD,&nbsp;Yutaka Furukawa MD","doi":"10.1016/j.amjcard.2024.09.001","DOIUrl":"10.1016/j.amjcard.2024.09.001","url":null,"abstract":"<div><div>Data regarding the incidence, time course, and outcomes of worsening tricuspid regurgitation (TR) after transvenous cardiac implantable electronic device (CIED) implantation are limited. We screened 834 consecutive patients who underwent first-time transvenous CIED implantation. After excluding patients without preoperative or follow-up echocardiography (n = 361) and patients with severe TR before implantation (n = 15), the present study population consisted of 458 patients. Worsening TR was defined as moderate or more TR that was newly developed or increased by at least 1 grade compared with baseline. During the median follow-up period of 2.1 years, worsening TR occurred in 93 patients (20%). The cumulative incidence of worsening TR was 10.2% at 1 year and 18.6% at 3 years. Of the 67 patients with worsening TR who underwent follow-up echocardiography, excluding those who underwent tricuspid valve surgery, 76% showed improvement in TR severity, with 70% having none or mild TR. On the landmark analysis, the 5-year cumulative incidence of all-cause death and heart failure hospitalization was significantly higher in patients with worsening TR at 1 year than those without worsening TR at 1 year (24.8% vs 11.4%, p = 0.002 and 35.2% vs 17.9%, p = 0.012, respectively). When considering worsening TR as a time-dependent covariate, worsening TR was significantly associated with an increased risk of all-cause death and heart failure hospitalization after adjustment for the differences in baseline patient characteristics (hazard ratio 1.99, 95% confidence interval 1.21 to 3.27, p = 0.006 and hazard ratio 2.64, 95% confidence interval 1.59 to 4.37, p &lt;0.001, respectively). In conclusion, worsening TR after transvenous CIED implantation was not uncommon and had a dynamic nature with an improvement in the majority of patients, suggesting the functional etiology. Nonetheless, worsening TR was independently associated with an increased risk for mortality and heart failure hospitalization.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiogenic Shock in Patients With Spontaneous Coronary Artery Dissection","authors":"Marcos García-Guimarães PhD ,&nbsp;Manel Sabaté PhD ,&nbsp;Ignacio Cruz-González PhD ,&nbsp;Ernesto Valero PhD ,&nbsp;Teresa Bastante MD ,&nbsp;Fernando Alfonso PhD ,&nbsp;investigators of the Spanish Registry on Spontaneous Coronary Artery Dissection","doi":"10.1016/j.amjcard.2024.08.018","DOIUrl":"10.1016/j.amjcard.2024.08.018","url":null,"abstract":"","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142054698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter Aortic Valve Replacement in Nonagenarians: A Finnish Multicenter Study","authors":"Matti Riihiniemi BM ,&nbsp;Jarkko Piuhola MD, PhD ,&nbsp;Matti Niemelä MD, PhD ,&nbsp;Yoichi Sugiyama MD, PhD ,&nbsp;Heidi Kiviniemi MD, PhD ,&nbsp;Fausto Biancari MD, PhD ,&nbsp;Mika Laine MD, PhD ,&nbsp;Mikko Savontaus MD, PhD ,&nbsp;Juhani Junttila MD, PhD","doi":"10.1016/j.amjcard.2024.08.030","DOIUrl":"10.1016/j.amjcard.2024.08.030","url":null,"abstract":"","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142131642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Cancer Therapy–Related Cardiac Dysfunction: A Case-Based Review","authors":"Jaya Mallidi MD, MHS ,&nbsp;Richard Baylis MD, PhD ,&nbsp;Evelyn J. Song MD","doi":"10.1016/j.amjcard.2024.08.029","DOIUrl":"10.1016/j.amjcard.2024.08.029","url":null,"abstract":"<div><div>With an ever-expanding repertoire of cancer therapies, cardiologists increasingly encounter patients with cancer therapy–related cardiac dysfunction. This can range from asymptomatic mild left ventricular dysfunction to severe symptomatic congestive heart failure. A multidisciplinary approach involving oncologists and cardiologists is needed in the management of these patients. This case-based review provides a practical guide for clinicians regarding the diagnosis and management of cancer therapy–related cardiac dysfunction associated with commonly used cancer treatments: anthracyclines, human epidermal receptor 2–targeted therapies, and immune checkpoint inhibitors.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0002914924006337/pdfft?md5=37a26264f4429f40a4ba419b02f37bb2&pid=1-s2.0-S0002914924006337-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142131641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved Risk Prediction Using a Refined European Guidelines Instrument in Pulmonary Arterial Hypertension Related to Congenital Heart Disease","authors":"Alexandra C. van Dissel MD, PhD ,&nbsp;Michele D'Alto MD, PhD ,&nbsp;Andrea Farro MD ,&nbsp;Harold Mathijssen MD, PhD ,&nbsp;Marco C. Post MD, PhD ,&nbsp;Pier P. Bassareo MD, PhD ,&nbsp;Arie P.J. van Dijk MD, PhD ,&nbsp;Barbara J.M. Mulder MD, PhD ,&nbsp;Berto J. Bouma MD, PhD","doi":"10.1016/j.amjcard.2024.08.027","DOIUrl":"10.1016/j.amjcard.2024.08.027","url":null,"abstract":"<div><div>The European guidelines advocate a goal-oriented treatment approach in pulmonary arterial hypertension (PAH), based on a comprehensive risk assessment instrument, which has been validated in several PAH subgroups. We investigated its discriminatory ability and explored tricuspid annular plane systolic excursion and revised thresholds to improve its predictability within the adult congenital heart disease (CHD) population.</div><div>In total, 223 adults (42 ± 16 years, 66% women, 68% Eisenmenger) were enrolled from 5 European PAH-CHD expert centers. Patients were classified as low, intermediate, or high risk at the baseline visit and at follow-up within 4 to 18 months. By the general PAH guidelines instrument, survival did not differ between the risk groups (p-value not significant), mostly because of the skewed group distribution. Reclassifying patients using revised thresholds for N-terminal pro–brain natriuretic peptide and 6-minute walk distance (i.e., low, intermediate, and high as &lt;500, 500 to 1,400, &gt;1,400 ng/L and &gt;400, and 165 to 400 and &lt;165 m, respectively) and use of tricuspid annular plane systolic excursion (low, intermediate, and high as &gt;20, 16 to 20, and &lt;16 mm, respectively) significantly improved the discrimination between the risk groups at baseline and follow-up (p = 0.001, receiver operating characteristic increase from 0.648 to 0.701), reclassifying 64 patients (29%). Irrespective of follow-up risk group, survival was better for patients with higher proportions of low-risk variables. Improvement to a low-risk profile at a median of 9 months of follow-up provided improved survival compared with the survival of patients who remained in the low-risk group.</div><div>In conclusion, the external validity of general risk instrument for PAH appeared to be of limited discriminatory value in patients with PAH-CHD. We propose a refined risk instrument with improved discrimination for PAH-CHD.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142131640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}